Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Aviir, Inc.
IRVINE, Calif., Oct. 23, 2013 /PRNewswire/ -- Aviir, Inc. announced its partnership with Qatar Heart Lab Holdings (QHLH), the investing arm of the TriValley Group Qatar, to expand Aviir's MIRISK® and MIRISK VP® cardiac assessment tests, which help diagnose the vulnerable patient at risk of cardiac events, to 19 countries throughout the Middle East and Asia.
With this partnership, Dr. Douglas Harrington, M.D., will join Qatar Heart Lab Holdings as Managing Director, while continuing to serve as Laboratory Director for Aviir. Aviir's COO Dan Angress has been appointed CEO to continue the growth of MIRISK and MIRISK VP in the U.S. Dr. Harrington stated, "Dan brings over 20 years of experience in building successful healthcare companies and will be an excellent leader for Aviir during this exciting growth and expansion."
On the heels of World Heart Day, international efforts kicked off last week in Indonesia at Bethesda Christian Hospital in Yogyakarta, the largest of 12 hospitals in the region. Aviir, QHLH, and partner GUARDaHEART, a non-profit organization dedicated to raising awareness of heart disease and prevention, met with government officials and healthcare authorities who are taking a proactive approach to finding and implementing solutions for heart disease detection and prevention.
The next international stop was Serbia, where Dr. Harrington and GUARDaHEART attended the XIX Congress of Cardiology Society of Serbia. Dr. Harrington addressed the Society with an introduction of Aviir's MIRISK and MIRISK VP tests that can help physicians significantly improve identification of "vulnerable patients" who are unaware they may be at risk of a heart attack.
With respect to the global expansion, Dr. Harrington stated, "We've worked tirelessly at Aviir to bring early detection and prevention to the forefront of the fight against heart disease in the U.S., and we're excited to bring these initiatives worldwide. The unmet clinical need in these countries is a tremendous opportunity to identify at-risk individuals missed by current practices, and to further preventive healthcare."
Aviir was founded in 2005 by a group of cardiologists and scientists from the Stanford University School of Medicine. Aviir is focused on the discovery, development, and commercialization of innovative diagnostic tests, with an emphasis on identifying patients at-risk of a cardiac event. Aviir's proprietary MIRISK and MIRISK VP cardiac tests have demonstrated significant improvement in the identification of individuals at risk of a heart attack. Aviir's CLIA-certified laboratory in Irvine, CA also offers a wide range of standard of care testing in addition to testing for cardiovascular assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders-including advanced pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools to help improve the cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. For more information, visit www.aviir.com.
GUARDaHEART is a non-profit foundation dedicated to raising awareness and powering prevention of heart disease by spreading the word to "guard your heart and save your life." Cardiovascular disease is the leading cause of death in the United States. GUARDaHEART is dedicated to promoting the fact that if individuals know their risk and take the necessary steps to lower the risk of heart disease, most cardiovascular disease is preventable. GUARDaHEART provides financial assistance for individuals who are unable to pay for cardiac risk assessments and supports programs and additional resources to lower the risk of heart disease. Please visit www.guardaheart.org and/or www.savethe1.org for more information.
About TriValley Group?
TriValley is a distinguished group of companies and a leader in numerous spheres of Finance, Commercial, Industrial, Electromechanical, Healthcare, and Construction within the state of Qatar. The highly esteemed group is owned by H.E Sheikh Khalid Bin Jabor Mohamed Al Thani, a prominent member of the ruling family.
About Qatar Heart Laboratory Holdings?
Qatar Heart Lab Holdings, (QHLH), is the investing arm of TriValley Group who holds the international distribution rights of the MIRISK® and MIRISK VP® cardiac tests that have demonstrated significant improvement in the identification of individuals at risk of heart attack. The Middle East and Asia have seen a steep rise in both obesity and diabetes, resulting in a parallel increase in cardiac disease and its complications in those societies. In the past decade, diabetic prevalence has reached more than 38 percent and obesity rates exceed 35 percent of the population in some Middle Eastern Countries. Qatar Heart Lab Holdings (QHLH) is dedicated to fight this global epidemic which remains the #1 killer worldwide.
(949) 398-6300 x 6355
QHLH or TriValley Group
+974 44 21 5522
©2012 PR Newswire. All Rights Reserved.